AS
ASMB.US Assembly Biosciences Inc
- Market cap
- USD 432M
- P/E
- 28.2x
- P/B
- 1.45x
- ROE
- -14.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ASMB.US undervalued?
Graham numberASMB.US trades 34.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Assembly Biosciences Inc fundamental analysis
No fundamental analysis for Assembly Biosciences Inc yet.
Assembly Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infec…
Full company profileAssembly Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Assembly Biosciences Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 9.02M | 14.8M | 16.0M | 79.1M | 6.25M | 0.00 | 7.16M | 28.5M | 72.3M | 32.7M |
| Gross Profit | -80.3K | -35.2M | -57.9M | 16.0M | -22.2M | 6.25M | -498K | -41.7M | -27.4M | 72.2M | 32.7M |
| Operating Income | -45.3M | -52.2M | -92.7M | -103M | -64.8M | -133M | -94.1M | -64.6M | -45.4M | -12.1M | -54.8M |
| EBITDA | -44.8M | -52.0M | -92.7M | -102M | -58.4M | -90.6M | -93.6M | -60.7M | -39.7M | -5.99M | -44.2M |
| Net Income | -44.3M | -42.8M | -90.8M | -97.6M | -62.2M | -130M | -92.1M | -61.2M | -40.2M | -6.12M | -44.3M |
| EPS | -26 | -24 | -40 | -28 | -16 | -36 | -23 | -13 | -6.69 | -0.55 | -2.03 |
| Balance Sheet | |||||||||||
| Total Assets | 98.1M | 169M | 268M | 348M | 283M | 191M | 102M | 137M | 119M | 258M | 325M |
| Total Liabilities | 18.2M | 56.2M | 57.4M | 74.7M | 42.7M | 22.1M | 19.1M | 95.7M | 85.8M | 50.8M | 26.5M |
| Shareholders' Equity | 79.9M | 113M | 211M | 273M | 241M | 169M | 82.7M | 41.1M | 33.4M | 207M | 299M |
| Cash & Short-term Investments | 53.0M | 120M | 218M | 274M | 216M | 147M | 91.6M | 130M | 112M | 248M | 314M |
| Total Debt | - | - | - | 12.3M | 10.1M | 6.48M | 3.47M | 2.34M | 3.09M | 2.63M | 2.21M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -34.9M | 1.86M | -65.0M | -84.1M | -63.0M | -93.4M | -84.5M | 22.7M | -51.1M | -41.1M | -73.0M |
| Capital Expenditure | 146K | 865K | 340K | 1.55M | 2.22M | 3.10M | 102K | 255K | 28.0K | 66.0K | 187K |
| Free Cash Flow | -35.0M | 996K | -65.3M | -85.6M | -65.2M | -96.5M | -84.6M | 22.5M | -51.1M | -41.2M | -73.2M |
| Ratios | |||||||||||
| ROE | -55.4% | -37.8% | -43.1% | -35.7% | -25.8% | -76.9% | -111.4% | -149.0% | -120.4% | -3.0% | -14.8% |
| ROA | -45.1% | -25.3% | -33.9% | -28.1% | -21.9% | -68.0% | -90.4% | -44.7% | -33.7% | -2.4% | -13.6% |
| Net Profit Margin | - | -474.7% | -613.0% | -611.6% | -78.6% | -2,076.4% | - | -854.8% | -140.9% | -8.5% | -135.2% |
| Debt to Equity | - | - | - | 0.04x | 0.04x | 0.04x | 0.04x | 0.06x | 0.09x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Assembly Biosciences Inc dividends
Assembly Biosciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Feb 12, 2024.
Who owns Assembly Biosciences Inc
- Insiders 27.99%
- Institutions 72.01%
- Public & others 0.00%
- Shares outstanding 20.5M
- Free float 9.19M
Top funds holding ASMB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 428K | 2.10% | +3.64% | Sep 2026 |
| iShares Russell 2000 ETF | 332K | 1.63% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 324K | 1.59% | +2.69% | Oct 2026 |
| iShares Russell 2000 Value ETF | 129K | 0.63% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 107K | 0.53% | 0.00% | Aug 2026 |
| Vanguard Russell 2000 ETF | 77.8K | 0.38% | +37.66% | Sep 2026 |
| BlackRock Advantage Small Cap Core Instl | 72.7K | 0.36% | +284.86% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 72.2K | 0.35% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 67.6K | 0.33% | +19.29% | Sep 2026 |
| Franklin Biotechnology Discovery A | 41.0K | 0.20% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 40.6K | 0.20% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 33.5K | 0.16% | +0.11% | Sep 2026 |
| Schwab Small Cap Index | 32.5K | 0.16% | +36.55% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 27.5K | 0.14% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 24.6K | 0.12% | +33.49% | Sep 2026 |
| Fidelity Total Market Index | 24.0K | 0.12% | +13.04% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 23.4K | 0.11% | +0.26% | Oct 2026 |
| Fidelity Series Total Market Index | 23.3K | 0.11% | +29.39% | Sep 2026 |
| Northern Small Cap Value | 20.7K | 0.10% | 0.00% | Sep 2026 |
| MFS Blended Research Small Cap Eq R6 | 18.7K | 0.09% | -0.64% | Sep 2026 |
Top institutions holding ASMB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Farallon Capital Management, L.L.C. | 1.60M | 7.88% | +30.71% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 1.55M | 7.63% | +133.56% | Jun 2026 |
| COMMODORE CAPITAL LP | 1.42M | 6.95% | +41.50% | Jun 2026 |
| RA Capital Management, LLC | 1.02M | 5.01% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 849K | 4.17% | 0.00% | Jun 2026 |
| BlackRock Inc | 767K | 3.77% | +278.22% | Jun 2026 |
| Parkman Healthcare Partners LLC | 721K | 3.54% | +75.37% | Jun 2026 |
| Vanguard Capital Management, LLC | 559K | 2.75% | +13.97% | Jun 2026 |
| Point72 Asset Management, L.P. | 461K | 2.26% | +33.85% | Jun 2026 |
| Seven Fleet Capital Management LP | 433K | 2.13% | +671.45% | Jun 2026 |
| Millennium Management LLC | 299K | 1.47% | +27.89% | Jun 2026 |
| Geode Capital Management, LLC | 280K | 1.38% | +110.89% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 242K | 1.19% | +100.96% | Jun 2026 |
| Ameriprise Financial Inc | 230K | 1.13% | 0.00% | Jun 2026 |
| DV EQUITIES, LLC | 226K | 1.11% | 0.00% | Jun 2026 |
| Aberdeen Group PLC | 207K | 1.02% | 0.00% | Jun 2026 |
| Affinity Asset Advisors, LLC | 190K | 0.93% | 0.00% | Jun 2026 |
| B Group, Inc | 176K | 0.86% | 0.00% | Jun 2026 |
| State Street Corp | 172K | 0.84% | +203.29% | Jun 2026 |
| StemPoint Capital LP | 170K | 0.84% | -54.06% | Jun 2026 |
Assembly Biosciences Inc company profile
- Company name
- Assembly Biosciences Inc
- Ticker
- ASMB.US
- Exchange
- USA Stocks
- Listed since
- Dec 17, 2010
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 73
- Fiscal year end
- December
- Address
- Two Tower Place, South San Francisco, CA, United States, 94080
- Phone
- 833 509 4583
- Website
- assemblybio.com
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Assembly Biosciences Inc management
10- Mr. Jason A. Okazaki J.D.CEO, President & Director · born 1976
- Dr. William E. Delaney IV, Ph.D.Chief Scientific Officer · born 1972
- Dr. Anuj Gaggar M.D., Ph.D.Chief Medical Officer · born 1978
- Ms. Jeanette M. BjorkquistPrincipal Financial Officer, Executive Director of Accounting & Treasury · born 1987
- Mr. Shannon RyanSenior Vice President of Investor Relations, Corporate Affairs & Alliance Management
- Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHRChief Human Resources Officer
- Dr. Nicole S. White Ph.D.Chief Manufacturing Officer · born 1980
- Ms. Katie KitrinosSenior VP of Preclinical Research & Development
- Mr. Thomas E. RollinsExecutive Officer · born 1956
- Amy Figueroa C.F.A.Investor Relations Consultant